Pulmokine Awarded $1.5 Million Stage B VITA Contract To Advance Inhaled Kinase Inhibitors For Pulmonary Arterial Hypertension
3/27/2014 9:03:51 AM
Rensselaer, NY, March 27, 2014 (GLOBE NEWSWIRE) -- Pulmokine announced it has been awarded a Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). Proceeds from the contract will be used to develop an inhaled PDGF receptor kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The VITA contract will fund the performance of studies that will support an Investigational New Drug (IND) application to be submitted to the FDA. The potential value of the award is approximately $1.5 Million over three years.
Help employers find you! Check out all the jobs and post your resume.
comments powered by